Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1

Interventions

TIC10 compound 5trametinib 4dabrafenib 4Crizotinib 3selpercatinib 2naxitamab 2entrectinib 2Trastuzumab 2Granulocyte-Macrophage Colony-Stimulating Factor 2AZD 6244 2vorasidenib 1ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1tovorafenib 1sodium thiosulfate 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1mirdametinib 1lutetium Lu 177 dotatate 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1copper dotatate CU-64 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × mirdametinib × CNS × Clear all
NCT03962543 2026-05-06

ReNeu

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
114 enrolled 25 charts 1 FDA
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡